IMGS-203

Houston – November 05, 2026 -- ImmunoGenesis has published two papers reporting nonclinical evidence that its STING agonist IMGS-203 remodels the tumor microenvironment and can be combined with the company's cytotoxic dual-specific PD-L1/PD-L2 antibody. The clinical-stage biotech plans to take IMGS-203 into clinical development first in recurrent glioblastoma (GBM).

IMGS-203 reduces immunosuppressive cells and improves survival in tumor models

Nonclinical studies show that local administration of IMGS-203 remodels the tumor microenvironment (TME) and reduces immunosuppressive myeloid cell populations. It also enhances T-cell activation and improves survival in tumor models.

GBM is a highly immunosuppressive, myeloid-rich tumor in which conventional immune checkpoint inhibitors have shown limited efficacy as monotherapy.

Houston – November 05, 2026 -- ImmunoGenesis will present IND-enabling data for IMGS-203, its novel STING agonist for recurrent glioblastoma (GBM), at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, running November 4-8 at the Phoenix Convention Center in Arizona.

ImmunoGenesis targets recurrent glioblastoma with IMGS-203 as its first clinical indication

The company plans to advance IMGS-203 into clinical development first for recurrent GBM, which it describes as an aggressive brain cancer with limited therapeutic options and significant unmet medical need. IMGS-203 is a Stimulator of Interferon Genes (STING) agonist designed to stimulate antitumor immune responses. The presentations will cover both the IND-enabling activities and the therapeutic potential of the candidate, in poster and oral formats.